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Abstract
Background: Periprosthetic joint infection (PJI) affects approximately 1 % of patients following total hip
replacement (THR) and often results in severe physical and emotional suffering. Current surgical treatment options
are debridement, antibiotics and implant retention; revision THR; excision of the joint and amputation. Revision
surgery can be done as either a one-stage or two-stage operation. Both types of surgery are well-established
practice in the NHS and result in similar rates of re-infection, but little is known about the impact of these
treatments from the patient’s perspective. The main aim of this randomised controlled trial is to determine whether
there is a difference in patient-reported outcome measures 18 months after randomisation for one-stage or two-
stage revision surgery.
Methods/Design: INFORM (INFection ORthopaedic Management) is an open, two-arm, multi-centre, randomised,
superiority trial. We aim to randomise 148 patients with eligible PJI of the hip from approximately seven secondary care
NHS orthopaedic units from across England and Wales. Patients will be randomised via a web-based system to receive
either a one-stage revision or a two-stage revision THR. Blinding is not possible due to the nature of the intervention. All
patients will be followed up for 18 months.
The primary outcome is the WOMAC Index, which assesses hip pain, function and stiffness, collected by questionnaire at
18 months. Secondary outcomes include the following: cost-effectiveness, complications, re-infection rates, objective hip
function assessment and quality of life. A nested qualitative study will explore patients’ and surgeons’ experiences,
including their views about trial participation and randomisation.
(Continued on next page)
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Discussion: INFORM is the first ever randomised trial to compare two widely accepted surgical interventions for the
treatment of PJI: one-stage and two-stage revision THR. The results of the trial will benefit patients in the future as the
main focus is on patient-reported outcomes: pain, function and wellbeing in the long term. Patients state that these
outcomes are more important than those that are clinically derived (such as re-infection) and have been commonly used
in previous non-randomised studies.
Results from the INFORM trial will also benefit clinicians and NHS managers by enabling the comparison of these key
interventions in terms of patients’ complication rates, health and social resource use and their overall cost-effectiveness.
Trial registration: Current controlled trials ISRCTN10956306 (registered on 29 January 2015); UKCRN ID 18159.
Keywords: Infection, Hip replacement, Revision, One-stage, Two-stage, Patient-reported outcome measures, Randomised
controlled trial, Cost-effectiveness
Background
Total hip replacement (THR) is a highly successful treat-
ment for painful and damaged joints, with over 80,000
primary THRs carried out in England, Wales and North-
ern Ireland in 2013 [1]. Periprosthetic joint infection
(PJI) is an uncommon but serious complication, affecting
approximately 1 % of patients who undergo primary
THR and is the indication for over 1,000 revision proce-
dures each year in the National Health Services of Eng-
land and Wales (NHS) [1, 2].
PJI occurring within 2 years of THR is mainly surgi-
cally acquired, and is associated with joint pain and re-
stricted movement. Early infections are commonly
caused by virulent bacteria and cause acute onset of
pain, effusion, erythema and fever. Delayed infections
typically present with symptoms similar to aseptic joint
failure including implant loosening and joint pain. If un-
treated, PJI can result in severe pain, restricted move-
ment, disability and death [3].
Treatment options for hip PJI are the following: surgi-
cal removal of devitalised, damaged and infected tissue
(debridement) with prosthesis retention and long-term
antibiotic treatment; one-stage revision; two-stage revi-
sion; excision or amputation. Surgical debridement and
retention is considered in early PJI with pathogens sus-
ceptible to antibiotics and in patients unfit for revision
THR. However, this approach may require lifelong anti-
biotic treatment [4].
Surgical revision for a hip PJI involves prosthesis re-
moval, debridement, antibiotic treatment and revision
THR. The prosthesis is replaced in the same operation
(one-stage) or replaced at a delayed interval of between
2 weeks and 12 months (two-stage). In a two-stage revi-
sion a temporary ‘spacer’ or temporary joint replacement
may be fitted, but the patient has no definitive THR until
it is replaced in the second operation. In England, Wales
and Northern Ireland in 2013, treatments were one-stage
(36 %), two-stage (60 %) and excision (4 %) [1].
The best treatment option is unclear. Two-stage revi-
sion has the potential for additional antimicrobial
treatment and strategies, but patients’ mobility and qual-
ity of life are poor between stages [5, 6]. One-stage revi-
sion is becoming increasingly popular because compared
with two-stage revision, it has the potential to reduce
the overall burden on patients of major surgery, and to
reduce healthcare costs [7].
To compare outcomes of one-stage and two-stage re-
vision of infected hip replacements, we systematically
reviewed studies that included populations representa-
tive of patients in routine clinical practice. Irrespective
of the surgical treatment used, the overall 2-year rate of
re-infection was 10.1 % (95 % CI 8.2–12.0). In 11 studies
with 1225 patients with a hip PJI receiving exclusively
one-stage revision, the rate of re-infection at 2 years was
8.6 % (95 % CI 4.5–13.9). After two-stage revision exclu-
sively in 28 studies with 1188 patients, the rate of re-
infection at 2 years was 10.2 % (95 % CI 7.7–12.9). We
conclude that on the basis of a systematic review of
published data, there is no difference in the re-
infection rate between one-stage and two-stage revi-
sion THR for PJI [8].
Rationale for the trial
Currently, both one-stage and two-stage revision THRs
are carried out for hip PJI. Surgeons from the collaborat-
ing centres are in agreement that a proportion of pa-
tients could be treated with either one-stage or two-
stage revision and that there is no definitive evidence to
recommend a specific strategy in terms of clinical or pa-
tient outcomes [9].
Unlike previous studies on infection after joint re-
placement, we plan to use patient-centred outcome mea-
sures rather than re-infection rates. This is because
patient and public involvement conducted at the lead
study centre during the development of this trial proto-
col, as well as previous research around outcomes after
surgery, show that patients are concerned about pain,
function and wellbeing after surgery, rather than a single
bio-medically defined outcome [10, 11]. This is particu-
larly relevant to PJI as treatment appears to be
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distressing and has a substantial impact on quality of life
[5, 9]. Qualitative research will form an integral part of
this trial, informing the design and development of trial
processes such as recruitment and randomisation, and
to facilitate the interpretation of the trial findings.
Null hypothesis
There is no difference in patient-reported outcomes (as
measured by the Western Ontario and McMaster Uni-
versities Arthritis (WOMAC) Index) at 18 months post
randomisation, after one-stage or two-stage revision
THR, for PJI.
Methods/Design
The Infection Orthopaedic Management (INFORM)
study is a pragmatic, multi-centre two-armed, parallel
group, open, randomised, superiority trial with 1:1 allo-
cation and a nested qualitative study.
The study obtained ethical approval from NRES Com-
mittee South West – Frenchay on 31 December 2014
(14/SW/1166).
Study setting
Patients will be initially recruited from seven NHS sec-
ondary care orthopaedic units in England and Wales. If
necessary, the trial will be enlarged to more centres to
achieve the recruitment target. Selected sites are high-
volume tertiary referral centres for infected joint replace-
ments or large NHS orthopaedic units. Participating sur-
geons at each centre have experience and expertise in
both one-stage and two-stage revision treatment.
Study duration
Recruitment into the trial commenced in March 2015
and 18-month follow-up for all participants is antici-
pated to be completed by August 2018.
Participants
Patients will be eligible for the study if they have a hip
PJI, and are deemed suitable for either one-stage or two-
stage revision surgery by their treating surgeon. The
diagnosis of infection, monitoring and decision to
proceed to revision surgery, will be determined by the
treating surgeon, or multidisciplinary team at the unit.
This pragmatic approach should mean that the results of
the trial are generalisable to the wider population of pa-
tients with this condition.
Patients will provide their written, informed consent
to participation before entering the study.
Inclusion criteria
 Aged 18 years or above
 A clinical diagnosis of hip PJI
 o Diagnosis will be guided by clinical,
haematological, biochemical, microbiological
and radiological findings from investigations
prior to surgery, in accordance with local
procedures and at the discretion of the treating
clinical team
 Require revision surgery (either one-stage or two-
stage revision THR) for hip PJI in the opinion of the
treating consultant orthopaedic surgeon(s)
Exclusion criteria
 Unable or unwilling to undergo either one-stage or
two-stage revision surgery
 Lacking capacity to give written informed consent
for research
Interventions
One-stage revision THR
One operation: the infected prosthetic joint is removed
along with any potentially infected materials, the surgical
site is debrided, irrigated and a new THR is implanted
under the same anaesthetic.
Two-stage revision THR
Two operations: in the first operation, the infected pros-
thetic joint is removed along with any potentially in-
fected materials and the surgical site is debrided and
irrigated. In a second operation, under a separate anaes-
thetic, a new THR is implanted. The antibiotic regime
between stages (e.g. duration, route) will be prescribed
according to local guidelines at each centre. The delivery
of local antibiotics and the use of a static or articulating
spacer will be determined by the treating surgeon de-
pending upon intra-operative findings at the time of the
first surgical intervention.
At the time of surgical intervention(s), all cases will
have tissue samples collected from five different sites
with clean instruments to allow an adequate number
and quality of samples to be available for microbiological
testing [12].
All other aspects of treatment (e.g. clinical investiga-
tions; surgical approach; pre-, peri- and post-operative
antibiotic regimens; choice of implants and fixation; an-
algesia) will be according to the treating surgeon’s nor-
mal practice and in line with local policies and
procedures.
Follow-up
Patients will remain in routine clinical follow-up, with
the frequency, duration and clinicians present (e.g. con-
sultant surgeon, microbiologist), determined by local re-
sources and clinical need. Response to treatment will be
monitored by blood tests (e.g. C-reactive protein) as
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clinically indicated and the occurrence of re-infection
will be determined by the presenting clinical history and
signs as elicited by the treating clinical team, consistent
with the preoperative diagnosis of infection.
Research assessments will take place preoperatively
(prior to one-stage or first of a two-stage revision), and
then every 3 months until 18 months post-
randomisation. Outcomes will be assessed using self-
report questionnaires, a clinical performance test and
extraction of data from medical records (Additional file
1: Figure S1).
Safety
Both interventions in the INFORM trial are common
surgical procedures for treating hip PJI in the NHS. Sur-
geons from the centres participating in the trial are ex-
perienced in these procedures and specialise in treating
PJI. There are no additional risks to patients in taking
part in the trial as the clinical interventions and follow-
up can be considered standard care. Regular monitoring
of outcomes may be perceived as a benefit to some. Pa-
tients will be informed of the risks of the operation dur-
ing the surgical consent process, as is standard practice.
All adverse events will be recorded and serious adverse
events will be notified to the appropriate authorities (Re-
search Ethics Committee and Sponsor) within specified
timelines.
Outcome measures
Primary outcome measure
The WOMAC Index measured at 18 months post-
randomisation.
The WOMAC Index is a validated patient-reported
outcome measure, widely used in THR research [13].
The index consists of 24 items (5 pain, 2 stiffness and 17
physical function) divided into three subscales and can
be completed in less than 12 minutes. Response options
are in a 5-point Likert scale format and the index is vali-
dated for completion on site or over the telephone [14].
Secondary outcome measures
Complications relating to the study:Complications relat-
ing to the study such as hip dislocation, deep vein
thrombosis/pulmonary embolism, nerve damage, add-
itional surgery, hospital readmissions, length of stay and
re-infection will be collected from hospital medical re-
cords and by telephone call or personal visit to partici-
pants, every 3 months post-randomisation for 18
months.
Post-operative pain
The Brief Pain Inventory short form (BPI-sf ) is a vali-
dated, widely used, self-administered questionnaire
which measures both the intensity of pain (sensory di-
mension) and interference of pain in the patient’s life
(reactive dimension). Patients will complete the eleven
questions (four on pain severity, seven on pain interfer-
ence) rated on a scale of 0–10. Other non-compulsory
items have been omitted [15].
Hip function
The Oxford Hip Score (OHS) is a short, self-
administered questionnaire, which has been validated for
use in THR. It consists of 12 questions about activities
of daily living directly affected by poor hip function [16].
The 20-metre timed walk test will be used as an ob-
jective measure of hip function. This will be performed
in hospital preoperatively and at 18 months post ran-
domisation [17].
Quality of life and mental wellbeing
The EuroQol EQ-5D-5 L is a validated quality of life
measure, consisting a descriptive system (five dimen-
sions; each dimension having five levels) and a visual
analogue scale (patient’s self-rated health recorded on a
20-cm scale) [18].
The Hip Dysfunction and Osteoarthritis Outcome
Score (HOOS), quality of life subscale consists of four
questions each on a 5-point Likert scale with each ques-
tion being scored from 0 to 4. A normalised score (100
indicating no symptoms and 0 indicating extreme symp-
toms) is calculated from the subscale. This instrument is
specifically designed to capture how the patient’s hip
symptoms impact on their lifestyle [19].
The Hospital Anxiety and Depression Scale (HADS) is
a validated self-reported measure used to detect anxiety
and depression in people with physical health problems.
The HADS comprises two subscales, depression and
anxiety. Each subscale has a score ranging from 0 to 21.
Items are rated on a 4-point Likert-type scale ranging
from 0 to 3, generating a scale range of 0 to 42 points,
with higher scores representing greater symptom sever-
ity [20].
Cost-effectiveness
All health service resource use relating to the hip PJI will
be collected from hospital records and from patient self-
completed questionnaires. This will include the interven-
tions, additional inpatient stays, outpatient appointments
and any related surgical or non-surgical procedures.
Questionnaires will collect information on non-treating
hospital resource use, community health and social ser-
vice use, travel costs, time off work and informal care.
Resource use logs, to act as an aide memoire, will be
given to patients at their initial preoperative assessment
to help them complete the follow-up questionnaires.
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Sample size
The required sample size has been set at 128 partici-
pants; allowing for a 13 % loss to follow-up at 18 months
post randomisation, a total of 148 patients will need to
be recruited. To reach this target, we will need to iden-
tify 290 eligible patients: the recruitment rate observed
in a surgical trial involving THR recently conducted in
the coordinating centre was 51 % with an attrition rate
of 13 % [21].
A sample size of 128 patients will provide 80 % power
to test that one surgical approach is superior to the
other approach 18 months post randomisation by 10
points on the WOMAC Index, equivalent to a 0.5 stand-
ard deviation difference. The significance level for this
superiority hypothesis is set at 5 % (two-sided).
Although it is known that infection following total
joint replacement reduces patient satisfaction and ser-
iously impairs functional health and quality of life, there
is no published research on the likely difference in
patient-reported outcomes between patients undergoing
one-stage and two-stage revision for PJI. The standard
deviations observed prior to one-stage or two-stage revi-
sion surgery for WOMAC global and sub-indices range
between 18 and 25 [22, 23].
Randomisation
After patients have been consented to the trial and have
agreed to be randomised, preoperative outcome mea-
sures will be collected. They will then be randomly allo-
cated to one of the two treatment groups (one-stage or
two-stage revision surgery) in a 1:1 ratio. Randomisation
within blocks of varying size will be conducted separ-
ately for each hospital. Block sizes will not be disclosed.
Randomisation will take place as close as possible to
the time of surgery (maximum 12 weeks prior to sur-
gery), whilst allowing sufficient time to plan the oper-
ation and order necessary equipment.
The randomisation sequence will be generated cen-
trally by computer, and administered via the Internet by
the Bristol Randomised Trial Collaboration.
Blinding
Due to the nature of the interventions, it is not possible
to blind patients or staff to allocation. Patients will be
informed of the allocated surgery after they have com-
pleted the preoperative assessments.
Statistical analysis
Analysis and presentation of data will be in accordance
with the Consolidated Standards of Reporting Trials
(CONSORT) guidelines for reporting randomised trials,
and the final report will also follow the CONSORT ex-
tension for non-pharmacological interventions (see Add-
itional file 1: Figure S1 – study flowchart). The baseline
characteristics and primary outcomes will be described
by treatment group. The secondary outcomes will also
be presented by treatment group and where required by
assessment point. Means with standard deviation or me-
dian with inter-quartile range will be reported for
continuous variable, frequency and proportions for cat-
egorical or binary variables, as appropriate.
The primary outcome is the continuous WOMAC
Index collected at 18 months postrandomisation. The
primary analysis will consist of a generalised linear
mixed model (GLLM) with identity link function regres-
sing baseline and 18-month WOMAC measures on the
treatment indicator (one-stage treatment versus two-
stage treatment), measurement point (baseline versus
18-months) and their interaction (treatment × measure-
ment point). This will be a two-level hierarchical GLLM
(measurements within patients). As the treatment alloca-
tion is stratified by hospitals and participants are nested
within a small number of hospitals, the primary analysis
will also be adjusted for indicators of hospital centre in-
troduced as fixed effects (using the coordination centre
as a reference). The intervention effect will be assessed
using appropriate contrast to identify the mean differ-
ence in WOMAC at 18 months and due emphasis will
be put on the associated 95 % confidence interval and
the p value resulting from the Wald-test associated with
this contrast. The primary analysis will be based on the
intention-to-treat principle, analysing participants in the
groups to which they were randomised. All individuals
with a WOMAC Index observed at baseline and/or at
18 months will be considered for this analysis. The
GLLM with identity link function is based on a likeli-
hood method, which provides unbiased estimation under
the missing at random hypothesis despite the presence
of missing outcome information. Various sensitivity ana-
lyses will be conducted to adjust for imbalance baseline
characteristics between treatment groups, assess the
clustering at surgeon level or investigate the impact of
missing data using various imputation strategies. Finally
a per-protocol analysis will be conducted.
Secondary analyses will firstly analyse all repeated
measurements of WOMAC to compare the trajectory of
recovery/change between treatment groups. Similarly to
the analyses of the WOMAC Index, we will firstly inves-
tigate the differences in OHS, HADS and 20-metre
timed walk test between treatment groups at 18 months
post randomisation (using a time × treatment group
interaction and appropriate contrast). We will then ana-
lyse all repeated measurements of those secondary out-
comes to compare the trajectory of recovery/change
between treatment groups. GLLMs with appropriate link
function will be used (using, according to the nature of
the outcomes, linear, logistic or Poisson two- or three-
levels mixed regression) to assess the difference between
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treatments in secondary outcomes and take into account
data clustering. Length of hospital stay will be assessed
and compared using generalised linear (Poisson or
negative-binomial) or survival analysis model. The trial
is not primarily powered for these analyses and the re-
sults will be interpreted with due caution.
Health economic analysis
We will conduct an intention-to-treat cost-effectiveness
analysis from a societal perspective with costs to the
NHS reported and analysed separately. All costs will be
reported in 2018/2019 prices, and discounting will be
applied as appropriate.
Health service resource use will be valued using hospital
finance department and routine UK data [24, 25]. Social
service, patient and informal carer resource use will be
valued using routine [25, 26] and self-reported data.
The net monetary benefit statistic, using the difference
in costs and the difference in quality-adjusted life years
(QALY) between groups, and adjusted for hospital
centre, baseline values (e.g. preoperative WOMAC, EQ-
5D-5 L) and any covariate imbalance, will be calculated
for different values of societal willingness to pay for a
QALY. This will be the primary economic analysis.
The secondary economic analysis will examine the dif-
ference in costs with the differences in the WOMAC
Index. If no arm is dominant, i.e. does not have statisti-
cally significant improved WOMAC Index and lower
costs, then an incremental cost-effectiveness ratio will be
estimated and cost-effectiveness acceptability curves will
be derived using bootstrapping techniques. These will
show the probability of the intervention being cost-
effective at a range of ‘willingness to pay’ thresholds.
Sensitivity analysis will account for uncertainty and
imprecision in measurements including multiple imput-
ation models for missing values.
Nested qualitative study
During the trial we will conduct a qualitative interview
study to explore patients’ experiences of taking part in
the trial, their treatment for PJI and their recovery. The
interviews will focus on the acceptability of the interven-
tions and patients’ experiences during the follow-up
period. Issues around mobility and return to function,
complications, expectations and perceptions of how they
feel that their treatment could be improved (if at all) as
well as any challenges faced during the recovery period
will be discussed.
We will interview up to 40 patients at two time points:
post intervention and at the end of the study (approximately
18 months later). We will also interview up to 20 surgeons
participating in the trial to explore the acceptability of the
trial recruitment and randomisation processes.
Findings from these interviews will help to refine trial
processes and inform an understanding of people’s expe-
riences and perceptions of the interventions and the care
they received.
The interviews will be audio-recorded, fully tran-
scribed, anonymised and analysed cross-sectionally and
longitudinally using framework method and constant
comparison.
Discussion
This paper describes a multi-centre randomised trial to
compare two widely accepted surgical interventions to
treat infected prosthetic hip joint replacements. The aim
is to establish the most patient-focussed and cost-
effective surgery to treat this devastating condition.
Randomised controlled trials (RCTs) are the highest
level of evidence available to assess the effectiveness of
surgical interventions. Despite this, there is a paucity of
robust, appropriately powered trials generally, and in the
field of orthopaedic surgical interventions specifically,
that utilise appropriate methodology. Whilst the nature
of the intervention (i.e. a different number of operations
being performed) means it is not possible to effectively
blind participants or surgeons to the intervention being
used, we have been able to address other common prob-
lems observed in surgical RCTs in our design. These in-
clude the lack of an a priori sample size calculation,
poorly defined inclusion and exclusion criteria, the use
of unvalidated outcome measures and lack of detail of
the statistical analysis employed [27–30]. The INFORM
trial will present generalisable data to support patient,
clinician and healthcare decision-making in the treat-
ment of patients with PJI of the hip.
Trial status
The INFORM trial received permission to conduct re-
search at the lead centre on 19 January 2015. The first
participant was enrolled on 4 March 2015.
Additional file
Additional file 1: Figure S1. Consort flow diagram. A visual
representation of the pathway of patients through the trial. (DOC 39 kb)
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